Literature DB >> 20862241

Would SYNTAX have been a positive trial if XIENCE V had been used instead of TAXUS?: A meta-analysis of a first-generation vs. a second-generation drug-eluting stent system.

B E Claessen1, G W Stone, P C Smits, E Kedhi, W J Kikkert, J J Piek, J P S Henriques.   

Abstract

Treatment options for coronary revascularisation include percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). In the 'synergy between PCI with TAXUS and cardiac surgery (SYNTAX)' trial, PCI and CABG using state-of-the-art techniques (using paclitaxel-eluting stents and arterial grafts, respectively) were compared in the treatment of complex coronary artery disease. In Syntax, PCI was inferior to CABG at one year, entirely due to an increased repeat intervention rate. We hypothesised that the use of a superior drug-eluting stent system could reduce the need for repeat intervention. (Neth Heart J 2010;18:451-3.).

Entities:  

Keywords:  Coronary Artery Bypass Surgery; Coronary Artery Disease; Drug Eluting Stents; Meta-analysis; Percutaneous Coronary Intervention

Year:  2010        PMID: 20862241      PMCID: PMC2941132          DOI: 10.1007/BF03091813

Source DB:  PubMed          Journal:  Neth Heart J        ISSN: 1568-5888            Impact factor:   2.380


  8 in total

1.  Would SYNTAX have been a positive trial if XIENCE V had been used instead of TAXUS?: A meta-analysis of a first-generation vs. a second-generation drug-eluting stent system.

Authors:  B E Claessen; G W Stone; P C Smits; E Kedhi; W J Kikkert; J J Piek; J P S Henriques
Journal:  Neth Heart J       Date:  2010-09       Impact factor: 2.380

2.  Clinical end points in coronary stent trials: a case for standardized definitions.

Authors:  Donald E Cutlip; Stephan Windecker; Roxana Mehran; Ashley Boam; David J Cohen; Gerrit-Anne van Es; P Gabriel Steg; Marie-angèle Morel; Laura Mauri; Pascal Vranckx; Eugene McFadden; Alexandra Lansky; Martial Hamon; Mitchell W Krucoff; Patrick W Serruys
Journal:  Circulation       Date:  2007-05-01       Impact factor: 29.690

3.  Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease.

Authors:  Gregg W Stone; Ali Rizvi; William Newman; Kourosh Mastali; John C Wang; Ronald Caputo; Julie Doostzadeh; Sherry Cao; Charles A Simonton; Krishnankutty Sudhir; Alexandra J Lansky; Donald E Cutlip; Dean J Kereiakes
Journal:  N Engl J Med       Date:  2010-05-06       Impact factor: 91.245

4.  Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease.

Authors:  Patrick W Serruys; Marie-Claude Morice; A Pieter Kappetein; Antonio Colombo; David R Holmes; Michael J Mack; Elisabeth Ståhle; Ted E Feldman; Marcel van den Brand; Eric J Bass; Nic Van Dyck; Katrin Leadley; Keith D Dawkins; Friedrich W Mohr
Journal:  N Engl J Med       Date:  2009-02-18       Impact factor: 91.245

5.  Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial.

Authors:  Gregg W Stone; Mark Midei; William Newman; Mark Sanz; James B Hermiller; Jerome Williams; Naim Farhat; Kenneth W Mahaffey; Donald E Cutlip; Peter J Fitzgerald; Poornima Sood; Xiaolu Su; Alexandra J Lansky
Journal:  JAMA       Date:  2008-04-23       Impact factor: 56.272

6.  One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II study.

Authors:  Peter N Ruygrok; Martin Desaga; Franck Van Den Branden; Klaus Rasmussen; Harry Suryapranata; Cécile Dorange; Susan Veldhof; Patrick W Serruys
Journal:  EuroIntervention       Date:  2007-11       Impact factor: 6.534

7.  Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial.

Authors:  Elvin Kedhi; Kaiyum Sheik Joesoef; Eugene McFadden; Jochem Wassing; Carlos van Mieghem; Dick Goedhart; Pieter Cornelis Smits
Journal:  Lancet       Date:  2010-01-07       Impact factor: 79.321

8.  Balloon-expandable intracoronary stents in the adult dog.

Authors:  R A Schatz; J C Palmaz; F O Tio; F Garcia; O Garcia; S R Reuter
Journal:  Circulation       Date:  1987-08       Impact factor: 29.690

  8 in total
  6 in total

Review 1.  Revascularization for left main and multivessel coronary artery disease in the drug-eluting stent era: integration of recent drug-eluting stent trials.

Authors:  Samip Vasaiwala; David O Williams
Journal:  Curr Cardiol Rep       Date:  2012-08       Impact factor: 2.931

2.  Would SYNTAX have been a positive trial if XIENCE V had been used instead of TAXUS?: A meta-analysis of a first-generation vs. a second-generation drug-eluting stent system.

Authors:  B E Claessen; G W Stone; P C Smits; E Kedhi; W J Kikkert; J J Piek; J P S Henriques
Journal:  Neth Heart J       Date:  2010-09       Impact factor: 2.380

3.  Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention for Unprotected Left Main Disease - A Review.

Authors:  Edward McNulty
Journal:  Interv Cardiol       Date:  2013-03

4.  Changes in the safety paradigm with percutaneous coronary interventions in the modern era: Lessons learned from the ASCERT registry.

Authors:  Alfredo E Rodríguez; Carlos Fernández-Pereira; Alfredo M Rodríguez-Granillo
Journal:  World J Cardiol       Date:  2012-08-26

5.  Are all stents equal - Need for scoring system to evaluate stents?

Authors:  Sundeep Mishra
Journal:  Indian Heart J       Date:  2016-09-09

6.  Classical determinants of coronary artery disease as predictors of complexity of coronary lesions, assessed with the SYNTAX score.

Authors:  J M Montero-Cabezas; I Karalis; R Wolterbeek; A O Kraaijeveld; I E Hoefer; G Pasterkamp; N H Pijls; P A Doevendans; J Walterberger; J Kuiper; A J van Zonneveld; J W Jukema
Journal:  Neth Heart J       Date:  2017-09       Impact factor: 2.380

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.